Human respiratory syncytial virus (RSV), also known as Human orthopneumovirus, is a multinucleated, enveloped, single-stranded RNA virus, which can affect any part of the respiratory tract and lead to intense inflammation. The infection is most severe when it affects the bronchioles leading to bronchiolitis. However, it can also affect any other part of the lungs leading to pneumonia. RSV is most likely to occur in premature infants, young children, elderly people, and adults with heart or lung diseases or with weakened immune systems, i.e. those individuals who are immunocompromised. It is a virus transmitted only between humans and is spread through secretions of mouth or nose of an infected individual. It has very similar symptoms to that of a moderate to severe cold. Cough, rhinitis, low-grade fever, and sore throat are all initial symptoms of an RSV infection. However, cyanosis, apnea and wheezing are all the severe symptoms of RSV developed in the later stage when the virus has already invaded the lower respiratory tract of an individual. There are two different strains of virus- Type A and Type B that may lead to differences in severity of illness.
The incubation time for virus, i.e. time from infection until the symptoms arrive is generally between 4 to 5 days. Diagnosis of an RSV infection is generally based on the findings of a physical examination. A blood test, chest X-rays, swab of secretion from inside the mouth or nose, and pulse oximetry are the basic tests conducted to diagnose the disease. An inclusive understanding of host pathogen interactions and viral replication in the host provides a basis for diagnosis, treatment, and development of vaccines and antiviral drugs for the disease.
The market is showing a significant growth on account of RSV being a major cause of respiratory diseases globally. Additionally, increased incidences of respiratory infections and rising neonatal population are also among the major factors driving the growth of the market. Development of drugs and vaccines with better effectiveness and limited drug toxicity in the upcoming years is also projected to positively impact the growth of the market, during the forecast period.
The global human respiratory syncytial virus treatment market is anticipated to project a CAGR of over 12%, during the forecast period (2019-2027). The market is segmented by route of administration into oral and parenteral form, out of which, the parenteral form segment is anticipated to witness higher demand in the global human respiratory syncytial virus treatment market on account of its high therapeutic concentrations that are achieved reliably and readily.
Get more information on this report: Download Sample PDF
Respiratory syncytial virus is among the leading causes of lower respiratory tract infections in infants and young children. This can be attributed to less therapeutic options available to prevent or treat disease which is expected to propel the market growth. According to the Centers for Disease Control and Prevention (CDC), in the US, there is an average of 1.5 million infant outpatient visits, out of which around 57,000 are hospitalized each year due to RSV infection.
Increased understanding of RSV biology for the development of drugs and vaccines to cure, treat, and prevent the infection owing to the innovations in technology is projected to drive the market growth.
Unavailability of approved drugs and vaccines for the treatment of RSV infection, due to lack of effectiveness and resistance against the infection is estimated to impede the growth of the market, over the forecast period.
Additionally, the high prices of monoclonal antibody injections used for the treatment and prevention of infection is also anticipated to hamper the market growth.
Our in-depth analysis of the global human respiratory syncytial virus treatment market includes the following segments:
On the basis of geography, the global human respiratory syncytial virus treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
The market in North America is expected to show a significant growth owing to the increased prevalence of viral infection among infants in this region. According to a survey conducted by the National Institute of Allergy and Infectious Diseases (NIAID), in the United States, all the two-year old children, become infected by RSV, with 75,000 to 125,000 of them being hospitalized every year. Moreover, an estimated of 64 million people get affected, out of which 160,000 deaths occur each year, globally.
The market in Asia Pacific is also anticipated to show a considerable growth as a result of the high population density and rising incidences of infections in the region.
The global human respiratory syncytial virus treatment market is further classified on the basis of region as follows:
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization